 ulcers compared to insured patients

157

(Scott et al. 1995a). Furthermore, disadvantaged populations have increased rates of recurrent
ulceration as well as delayed healing times. This is explained in part by the high cost of
treatment for patients with CVI, though delayed treatment of advanced disease ultimately
results in a greater overall cost burden (Y. Kim et al. 2021a).
When CVI progresses to its advanced stages